Transcript Document

Prospects for Pharmaceuticals:
Selling our Strengths Abroad
Jon Mowles, UKTI Sector Specialist
Japan Society 9th Nov ‘11
Setting the scene

The UK is ranked as the best performer in the G8 leading economies per unit of
R&D spend.

4 of the top 6 rated universities in the world are in the UK viz. Cambridge,
University College London, Imperial College and Oxford.

5 of the top 20 medicines in terms of global sales were developed in the UK.

In the last 10 years Life Sciences departments within UK universities have
generated over 200 spin-out companies, now employing over 1,000 people.
Benefits:
 The United Kingdom is a global centre of excellence in Life Sciences where:
–
–
–
–
Innovation is readily commercialised.
People are highly skilled and motivated.
Government is supportive and businesses prosper.
High value given to R&D.
2
Pharmaceutical:
Global FDI - 2006 - 10
Destination
City
No of
Projects
2006-2010
Singapore
39
8%
Shanghai
26
65
6%
Beijing
14
UK
61
6%
Budapest
13
Germany
59
5.5%
Prague
11
Ireland
46
4%
Mumbai
10
Singapore
39
3.5%
France
38
3.5%
Tokyo
10
Russia
35
3%
Dublin
10
Canada
30
2.8%
Sao Paulo
9
Berlin
9
Hyderabad
9
Moscow
9
Destination
Country
No of Projects
2006-2010
% of global
FDI
USA
119
11%
China
85
India
 Time Series: January 2006- December 2010
3
Source: fDi Markets™
Pharmaceutical:
UK FDI 2006 - 10
- On average the UK is recipient of 12 Pharmaceutical
projects per annum.
- Motives for UK investment in sector both skilled
workforce and proximity to market were cited as
primary drivers.
- R&D accounted for 39% of Pharmaceutical investment
followed by manufacturing and sales, support &
marketing.
- UK hubs of investment were identified in London,
Cambridge and Scotland.
Attractiveness / Quality of Life
Universities or researchers
Technology or Innovation
Industry Cluster / Critical Mass
Facilities Site or Real Estate
Domestic Market Growth Potential
IPA or Govt support
Infrastructure and logistics
•
Skilled workforce availability
Proximity to markets or customers
0%
5%
10%
15%
20%
TOP UK INVESTORS (2006 – 2010):
Quintiles; Pfizer; Nicholas Piramal India (NPIL);
Amgen; Icon; Warner Chilcott; Kendle
International; Eisai; Intercell; Novartis; Granules
India; Patheon; Clariant; Wyeth; Merck KGaA;
Glenmark Pharmaceuticals; Teva Pharmaceutical
Industries; UCB Group; Sanofi-Aventis; Evotec OAI;
Bilcare
4
Biopharma:
Global FDI - 2006 - 10
Destination
Country
No of Projects
2006-2010
% of global
FDI
USA
79
16%
UK
59
China
Destination
Cities
No of
Projects
20062010
13%
Singapore
23
38
8%
Shanghai
16
India
33
7%
London
12
Germany
29
6%
Boston (MA)
8
Singapore
23
5%
Dubai
7
France
16
3.5%
Beijing
6
Belgium
13
3%
Bangalore
6
Netherlands
12
3%
Dublin
6
Ireland
12
3%
Tokyo
6
Cambridge
6
 Time Series: January 2006- December 2010
5
Source: fDi Markets™
Biopharma:
UK FDI 2006 - 10
- On average the UK is recipient of 12
Biotechnology projects per annum.
- Motives for UK investment in sector – 26%
surveyed cited Government support as key
driver.
- R&D accounted for 41% of Biotechnology
investment in the UK 2006-2010. Sales,
marketing and support accounted for 30%.
- UK hubs of investment were identified in
London, Cambridge and Scotland.
Infrastructure and logistics
Industry Cluster / Critical Mass
Finance Incentives or Taxes or Funding
Facilities Site or Real Estate
Domestic Market Growth Potential
Technology or Innovation
•
Skilled workforce availability
Universities or researchers
Proximity to markets or customers
IPA or Govt support
0% 5% 10% 15% 20% 25% 30%
TOP UK INVESTORS (2006 – 2010):
Life Technologies (Invitrogen); SigmaAldrich; Millipore; Genzyme; Pfizer;
Magellan Biosciences; Bioanalytical Systems
(BASi); Bristol-Myers Squibb; ScheringPlough; Wyeth; Serologicals; Waters;
Eurofins Scientific; Cognia; BioMarin
Pharmaceutical; MatriCal; Fziomed;
IdentiGEN; BioGuard Components &
Technologies; MediciNova
6
UK BioPharma Networks
Scotland (Edinburgh, Dundee, Aberdeen)
• Human and animal healthcare
• Environmental biotechnology
• Gene therapy
• Protein engineering
• Combinatorial chemistry
North (Manchester, York, Liverpool, Newcastle)
• Bio-health informatics
• Genomics and Proteomics
• Medical Imaging
• Clinical Genetics
• Bio-manufacturing
• Agricultural/Food Sciences
Cambridge
• Biopharmaceuticals
• Drug discovery-genomics,
• proteomics
• bioinformatics
• combinatorial chemistry
• Protein/DNA sequencing/engineering
• Biomaterials
Northern Ireland
• Diagnostics
• Agriculture
• Veterinary medicine
• Food Sciences
• Environmental
Oxford
• Proteomics
• Genomics
• Chemical libraries
• Vaccines
• Monoclonal antibodies
Wales
• Diagnostics
•Healthcare
• Biotechnology
Surrey
• Agricultural biotechnology
• Production of reagents: cell/tissue cultures
London
• Biopharmaceuticals
• Decoding/transformation of DNA material
• Functions of sub-cellular organisms
• Functional genomics
(Source: UKTI Sector Group, 2007)
7
UKTI: Conclusions
1. Within the Life Sciences Sector, the UK is a good place to do business
2. UK Trade & Investment is the UK Government organisation that:

Helps overseas companies to bring high quality investment to the UK economy.

Helps UK-based companies access international markets to succeed in an
increasingly global economy.

Works with existing foreign investors to grow their business in the UK and
internationally.

A global network. UKTI has staff in British Embassies, High Commissions and
other diplomatic offices around the world.

UK Trade & Investment – Winner 2010: Best Trade Promotion
Organisation in the developed world

UKTI LOOKS TO ADD VALUE!
8
Jon Mowles
Life Sciences Sector Specialist
Investment Directorate - London
UK Trade & Investment
[email protected]
Tel: +44 (0) 7826 912 923
UKTI Website: www.uktradeinvest.gov.uk
9